| Literature DB >> 25236175 |
Nicolas D Knuth1, Darcy L Johannsen, Robyn A Tamboli, Pamela A Marks-Shulman, Robert Huizenga, Kong Y Chen, Naji N Abumrad, Eric Ravussin, Kevin D Hall.
Abstract
OBJECTIVE: To measure changes in resting metabolic rate (RMR) and body composition in obese subjects following massive weight loss achieved via bariatric surgery or calorie restriction plus vigorous exercise.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25236175 PMCID: PMC4236233 DOI: 10.1002/oby.20900
Source DB: PubMed Journal: Obesity (Silver Spring) ISSN: 1930-7381 Impact factor: 5.002
Anthropometric and energy metabolism measurements in 13 pair-matched BLC and RYGB subjects.
| BLC | RYGB | ||||
|---|---|---|---|---|---|
| Baseline | 7 months | Baseline | 6 months | 12 months | |
| Age (y) | 32 ± 11 | 39 ± 9 | |||
| Body weight (kg) | 139.6 ± 35.6 | 90.8 ± 25.4 | 135.0 ± 28.0 | 106.6 ± 25.3 | 94.9 ± 21.6 |
| Body weight change (kg) | −48.8 ± 14.9 | −35.6 ± 8.7 | −40.2 ± 12.7 | ||
| Percent weight change | −35.0% ± 7.1% | −25.2% ± 4.6% | −29.6% ± 7.0% | ||
| BMI (kg/m2) | 47.6 ± 9.5 | 30.9 ± 6.8 | 47.0 ± 7.6 | 36.3 ± 7.3 | 33.0 ± 6.4 |
| Fat-free mass (kg) | 70.4 ± 18.6 | 62.4 ± 15.9 | 69.8 ± 16.5 | 63.8 ± 16.9 | 58.3 ± 15.6 |
| Fat mass (kg) | 69.2 ± 20.9 | 28.5 ± 14.4 | 65.3 ± 17.1 | 42.8 ± 15.2 | 36.6 ± 12.6 |
| Percent body fat | 49.5% ± 5.6% | 30.4% ± 9.5% | 48.3% ± 6.6% | 39.9% ± 9.6% | 38.4% ± 9.7% |
| Weight loss proportion: | |||||
| Fat-free mass | 16.4% ± 8.1% | 29.2% ± 13.5% | 29.6% ± 11.9% | ||
| Fat mass | 83.6% ± 8.1% | 70.8% ± 13.5% e | 70.4% ± 11.9% | ||
| Average energy imbalance (kcal/d) | −1848 ± 584 | −1382 ± 436 | −779 ± 285 | ||
| RMR measured (kcal/d) | 2474 ± 477 | 1857 ± 463 | 2128 ± 291 | 1754 ± 377 | 1832 ± 196 |
| RMR predicted (kcal/d) | 2564 ± 408 | 2275 ± 330 | 2142 ± 353 | 1955 ± 351 | 1824 ± 320 |
| Metabolic adaptation (kcal/d) | −419 ± 169 | −201 ± 182 | 8 ± 191 | ||
Data are presented as mean ± SD.
Statistical analysis of 6-month RYGB data in comparison to baseline or 12-month RYGB data is limited to same 9 subjects at all time points; statistical analysis of 6-month RYGB data in comparison to 7-month BLC data is limited to within the 9 pairs.
Predicted RMR was calculated from the best-fit linear regression to baseline data (R2 = 0.80): RMRpredict= 1026 kcal/d + FFM×19.8 kcal/kg/d + FM×3.1 kcal/kg/d − age×2.3 kcal/y/d - group×381 kcal/d
p < 0.01,
p < 0.05 – denotes a significant difference from the within-group baseline
p < 0.01,
p < 0.05 – denotes a significant difference from BLC 7-month
Denotes a significant difference from BLC baseline, p < 0.05
Denotes a metabolic adaptation significantly different from zero, p < 0.01
Denotes a significant difference from RYGB 6-month, p < 0.01
Figure 1Percentage of total weight loss from fat mass (FM) and fat-free mass (FFM) in 13 pair-matched BLC and RYGB participants (mean ± SD). * P < 0.01 BLC percentage of total weight loss from fat mass significantly different from RYGB. † P < 0.01 BLC percentage of total weight loss from fat-free mass significantly different from RYGB.
Figure 2Metabolic adaptation (measured minus predicted RMR) in BLC (●) at baseline and 7 months; and in RYGB (□) at baseline (n=13), 6 months (n=9), and 12 months (n=13) (mean ± SD). * P < 0.01 metabolic adaptation significantly different from zero. † P < 0.05 compared with BLC 7 month.
Figure 3Correlation between metabolic adaptation and (A) average energy imbalance (r = 0.55, p =0.004) and (B) percent decrease in circulating leptin (r = 0.47, p =0.02) in BLC at 7 months (●) and RYGB at 6 months (■) and 12 months (□). Linear correlations were calculated for all data combined.
Biochemical and blood pressure measurements in 13 pair-matched BLC and RYGB participants.
| BLC (n=13) | RYGB (n=13) | |||
|---|---|---|---|---|
| Baseline | 7 Months | Baseline | 12 Months | |
| 97 ± 17 | 78 ± 5 | 113 ± 42 | 88 ± 9 | |
| 8.0 ± 7.5 | 4.2 ± 1.9 | 25.5 ± 11.9 | 9.2 ± 3.9 | |
| 2.0 ± 2.1 | 0.8 ± 0.3 | 8.1 ± 8.6 | 2.0 ± 1.0 | |
| 45.2 ± 18.4 | 3.2 ± 2.4 | 36.8 ± 13.4 | 16.4 ± 10.5 | |
| 2.9 ± 1.1 | 4.8 ± 1.7 | 8.1 ± 5.5 | 14.7 ± 8.0 | |
| 2.5 ± 1.3 | 1.4 ± 1.0 | 4.2 ± 1.1 | 2.0 ± 0.3 | |
| 116 ± 82 | 58 ± 24 | 175 ± 59 | 96 ± 36 | |
| 168 ± 40 | 192 ± 48 | 192 ± 29 | 155 ± 23 | |
| HDL (mg/dL) | 44 ± 18 | 53 ± 14 | 44 ± 11 | 47 ± 9 |
| LDL (mg/dL) | 100 ± 28 | 127 ± 41 | 113 ± 26 | 89 ± 20 |
| Triiodothyronine (T3; nmol/L) | 1.30 ± 0.29 | 0.74 ± 0.16 | 1.64 ± 0.41 | 1.53 ± 0.23 |
| Thyroxin (T4; nmol/L) | 90.6 ± 18.5 | 82.3 ± 17.5 | 81.4 ± 9.4 | 82.2 ± 9.0 |
| Thyroid stimulating hormone (TSH; mIU/L) | 1.3 ± 1.0 | 1.1 ± 0.8 | 0.7 ± 0.5 | 0.7 ± 0.7 |
| 132 ± 8 | 118 ± 11 | 132 ± 18 | 122 ± 13 | |
| 82 ± 8 | 72 ± 10 | 78 ± 13 | 75 ± 12 | |
Data are presented as mean ± SD.
p < 0.01,
p < 0.05 – denotes significant difference from BLC baseline
p < 0.01,
p < 0.05 – denotes significant difference from respective baseline
p < 0.01,
p < 0.05 – denotes significant difference from BLC 7 month
HOMA-IR: homeostatic model assessment-estimated insulin resistance